Colonoscopic surveillance in patients with inflammatory bowel disease (IBD) may lower the risk of developing colorectal cancer (CRC) and death associated with it, according to a Cochrane review of 5 trials involving nearly 7,200 individuals. Among the findings, based on very low-quality evidence:
- The surveillance group had lower cancer rates; odds were reduced by 42%.
- The surveillance group had lower rates of CRC-related death; odds were reduced by 64%.
- The surveillance group had more early state disease detected.
Bye W, Nguyen T, Parker C, Jairath V, East J. Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database of Syst Rev. 2017, Issue 9. Art. No.: CD000279. doi:10.1002/14651858.CD000279.pub4.
This Week's Must Reads
ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al
Cochrane On Bisphosphonates for Prostate Cancer, Cochrane; 2017 Dec 26; Macherey, Monsef, et al
Cochrane on Vaccine-Based Immunotherapy for NSCLC, Cochrane; 2017 Dec 16; Zhu, Li, Tiselius, et al
Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22
Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20
Must Reads in Gastroenterology
Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al
Cochrane on Detecting CRC in Patients with IBD, Cochrane; 2017 Sep 18; Bye, Nguyen, Parker, et al
FDA Approves Keytruda for Advanced Gastric Ca, Merck news release; 2017 Sep 22
FDA Approves Opdivo for Hepatocellular Carcinoma, Bristol-Myers Squibb news release; 2017 Sep 22
Cochrane on Heparin Impact in People with Cancer , Cochrane; 2017 Sep 11; Akl, Kahale, et al